Abstract:Envelope proteins drive virus and host-cell membrane fusion to achieve virus entry. Fusogenic proteins are classified into structural classes that function with remarkable mechanistic similarities. Fusion proceeds through coordinated movements of protein domains in a sequence of orchestrated steps. Structures for the initial and final conformations are available for several fusogens, but folding intermediates have largely remained unresolved and interdependency between regions that drive conformational rearrangements is not well understood. Chikungunya virus (CHIKV) particles display heterodimers of envelope proteins E1 and E2 associated as trimeric spikes that respond to acidic pH to trigger fusion. We have followed experimental evolution of CHIKV under the selective pressure of a novel small-molecule entry inhibitor. Mutations arising from selection mapped to two residues located in distal domains of E2 and E1 heterodimer and spikes. Here, we pinpointed the antiviral mode of action to inhibition of fusion. Phenotypic characterization of recombinant viruses indicated that the selected mutations confer a fitness advantage under antiviral pressure, and that the double-mutant virus overcame antiviral inhibition of fusion while single-mutants were sensitive. Further supporting a functional connection between residues, the double-mutant virus displayed a higher pH-threshold for fusion than single-mutant viruses. Finally, mutations implied distinct outcomes of replication and spreading in mice, and infection rates in mosquitoes underscoring the fine-tuning of envelope protein function as a determinant for establishment of infection. Together with molecular dynamics simulations that indicate a link between these two residues in the modulation of the heterodimer conformational rearrangement, our approach captured an otherwise unresolved interaction. Importance. CHIKV is a reemergent pathogen that has caused large outbreaks in the twenty years. There are no available antiviral therapies and a vaccine has only recently been approved. Here, we describe the mode of action of a novel inhibitor designed against CHIKV envelope proteins heterodimer that blocks entry at the stage of fusion between virus and host membranes. Fusion is common to the entry of enveloped viruses. Virus envelope proteins drive fusion undergoing a series of transitions from an initial metastable conformational state to a more stable post-fusion state. Intermediate conformations are transient and have mostly remained inaccessible to structure determination. In this study, directed evolution of resistance to antiviral inhibition of fusion uncovered a functional interaction between two residues residing in domains that are apart in both the pre-fusion and post-fusion states. Thus, our approach allowed gaining insight into the molecular detail of the inner working of virus fusion machinery.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to understand the functional mechanism of the chikungunya virus (CHIKV) envelope protein in the process of virus - host cell membrane fusion, especially how antiviral drugs affect this process and how the virus overcomes this inhibitory effect through mutation. Specifically: 1. **Mechanism of action of antiviral drugs**: Researchers have discovered a small - molecule compound 11 that can inhibit CHIKV infection. Through a series of experiments, the researchers determined the specific mechanism of action of compound 11, that is, it prevents virus infection by inhibiting the membrane - fusion process mediated by the CHIKV envelope protein. 2. **Mechanism of virus mutation resistance to antiviral drugs**: Researchers screened out CHIKV mutants resistant to compound 11 by the method of experimental evolution. These mutations are mainly concentrated on envelope proteins E1 and E2, especially at two sites, E2 - P173S and E1 - Y24H. Further research shows that there is a functional interaction between these two mutation sites, which jointly regulate the virus fusion process, enabling the virus to overcome the inhibitory effect of compound 11. 3. **Effect of mutations on virus adaptability**: Researchers also explored the effects of these mutations on the adaptability of the virus in different hosts (such as mice and mosquitoes). The results show that the E2 - P173S and E1 - Y24H mutations have a positive impact on the replication and transmission ability of the virus in mice, but the infection rate in mosquitoes decreases. This indicates that these mutations have different adaptive effects in different hosts. 4. **Molecular dynamics simulation**: In order to understand the functional interaction between E2 - P173 and E1 - Y24 more in - depth, researchers carried out molecular dynamics simulation and constructed a residue - interaction network (RIN). The results show that these two sites are near the important hinge regions of the envelope protein and may affect the virus fusion mechanism by regulating the kinetic process of protein conformational changes. In summary, through various experiments and analyses, this paper reveals the complex regulatory mechanism of the CHIKV envelope protein in the membrane - fusion process and how the virus overcomes the inhibitory effect of antiviral drugs through specific mutations. These findings not only enhance the understanding of the CHIKV infection mechanism but also provide an important theoretical basis for the development of new antiviral strategies.

Evolution of antiviral resistance captures a transient interdomain functional interaction between chikungunya virus envelope glycoproteins

Changes in the chikungunya virus E1 glycoprotein domain II and hinge influence E2 conformation, infectivity, and virus-receptor interactions

Structural Transition and Antibody Binding of EBOV GP and ZIKV E Proteins from Pre-Fusion to Fusion-Initiation State

The effect of amantadine on an ion channel protein from Chikungunya virus

Structural Analyses at Pseudo Atomic Resolution of Chikungunya Virus and Antibodies Show Mechanisms of Neutralization

Suramin Inhibits Chikungunya Virus Replication by Interacting with Virions and Blocking the Early Steps of Infection

Interaction of chikungunya virus glycoproteins with macrophage factors controls virion production

Structural basis of Chikungunya virus inhibition by monoclonal antibodies

Identifying novel chemical matter against the Chikungunya virus nsP3 macrodomain through crystallographic fragment screening

Understanding Zika Virus Stability and Developing a Chimeric Vaccine Through Functional Analysis

Cryo-EM structures elucidate neutralizing mechanisms of anti-chikungunya human monoclonal antibodies with therapeutic activity.

Structure-based Discovery of Antiviral Inhibitors Targeting the E Dimer Interface of Japanese Encephalitis Virus.

A novel interaction between the 5' untranslated region of the Chikungunya virus genome and Musashi RNA binding protein is essential for efficient virus genome replication.

In silico identification and in vitro antiviral validation of potential inhibitors against Chikungunya virus

Natural Variation in HIV-1 Entry Kinetics Map to Specific Residues and Reveal an Interdependence Between Attachment and Fusion

The Molecular Mechanism of Enveloped Virus-Cell Membrane Fusion

Repurposing efavirenz, the HIV antiretroviral drug for Chikungunya virus infection

Viral entry mechanisms: the role of molecular simulation in unlocking a key step in viral infections

Chikungunya virus vaccine: a decade of progress solving epidemiological dilemma, emerging concepts, and immunological interventions

A Hydrophobic Target: Using the Paramyxovirus Fusion Protein Transmembrane Domain To Modulate Fusion Protein Stability